Compare Navan Inc. Class A Common Stock (NAVN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navan Inc. Class A Common Stock vs Natera Inc. Common Stock — how do they compare? Navan Inc. Class A Common Stock trades at $23.66 (market cap $6.22B), while Natera Inc. Common Stock trades at $392.22 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 9.2× Navan Inc. Class A Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Navan Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| NAVN | NTRA | |
|---|---|---|
Market Cap | $6.22B | $57.03B |
Volume | 2,173,244 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $30.58 | $425.64 |
52-Week Low | $8.51 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.57B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Navan (NAVN) trades at $23.9, up 1.44% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong revenue growth of 35% year-over-year in Q2 2027 to $233 million, beating earnings expectations, yet remains unprofitable with a net income margin of -42.11%. Recent developments include the acquisition of BoomPop and a partnership with Engine to expand its AI-powered travel platform.
The outlook is mixed: unanimous analyst buy ratings and a $30.56 price target suggest 27.5% upside, driven by growth execution. However, high debt, persistent losses, insider selling, and ongoing legal investigations pose significant risks. The stock's valuation appears stretched given current profitability challenges.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
